16:26 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Arrowhead raises $60.4M follow-on

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) raised $60.4 million through the sale of 11.5 million shares at $5.25 in a follow-on, including a 1.5 million share overallotment, on Jan. 22. Jefferies, Barclays Capital, Cantor Fitzgerald, Chardan...
22:21 , Oct 12, 2017 |  BC Innovations  |  Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
22:34 , Sep 28, 2017 |  BC Extra  |  Preclinical News

Arrowhead paper reveals additional HBV antigen source

A paper published in Science Translational Medicine by researchers at Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and colleagues discovered that hepatitis B surface antigen (HBsAg) is expressed from HBV DNA transcripts integrated into the host genome in...